The group’s purchase of Affiris’s Parkinson’s portfolio comes after stumbles from Roche/Prothena and Biogen.
Up-front costs are higher than ever, with preclinical and phase 2 assets showing the most price inflation, according to a new analysis of licensing deal trends.
Selective oestrogen degraders, or Serds, remain in focus as a key period for reporting clinical data approaches.
Pfizer/Biontech's and Astrazeneca’s Covid-19 vaccines come out strong in an analysis of thousands of UK cases of the Delta variant.
An FDA advisory committee refuses to overlook the potential dangers of roxadustat, Fibrogen's novel anaemia pill, leaving partner Astrazeneca with a difficult…
Big pharma delivered 76 novel medicines to the market over the past five years, but some companies contributed more than others.
Big risers include Eli Lilly, Biogen, Moderna and Biontech.
And Lilly was well ahead of the pack, fuelled by Alzheimer’s hopes.